Steward Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Steward Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$0	Buy	+3	New	+$339	﹤0.01%	1553

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Steward Financial Group's SRPT Position: Q3 2023 in Review

Steward Financial Group opened a new position in Sarepta Therapeutics (SRPT) in Q3 2023: 3 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1553 among its holdings.

394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Steward Financial Group held 3 shares of Sarepta Therapeutics worth $0 as of Q3 2023.
Sarepta Therapeutics was a new Steward Financial Group position in Q3 2023.
Sarepta Therapeutics made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1553 holding.
394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.